Doctor Profile

Doctor Profile
Tan Shao Weng Daniel
Dr Tan Shao Weng Daniel
National Cancer Centre Singapore
Medical Oncology
Senior Consultant
BSc (Hons), MBBS (London), MRCP (UK), FAMS

Dr Daniel Tan is a Senior Consultant at the Division of Medical Oncology and a Clinician-Scientist Fellow at Genome Institute of Singapore.  His main area of interest is in thoracic, head and neck malignancies and he currently leads the phase I unit where he is the principal investigator for multiple biomarker-driven early phase clinical trials including first-in-human studies.   His research has won multiple international awards, including European Society of Medical Oncology Congress Travel Award, American Society of Clinical Oncology (ASCO) Merit Awards and an ASCO Young Investigator Award.   He currently serves on the Education Committee of the International Association for Study of Lung Cancer is an Associate Editor for Journal of Thoracic Oncology.  His current research interests include rational application of “omics” technologies to unravel drug resistance in cancer therapeutics and accelerating the development of novel agents and biomarkers in the clinic.

Professional Appointments and Committee Memberships

2013 to date      Director, Experimental Cancer Therapeutics Unit (Phase I Unit), NCCS

2013 to date      Member, Pharmacokinetic/Pharmacodynamic Workgroup, Singhealth

2013 to date      Member, Education Committee, International Association for Study of Lung Cancer

2011 to date      Adjunct investigator, Investigational Medicine Unit

2011 – 2012       Clinician-Scientist member, Early Career Scientists of NCCS (EcSON)

2010 – 2012       Secretary, Singapore Society of Oncology

Awards

1998 Practical Project Prize (For Best B.Sc. Dissertation), University College London 
 
2000 Turnbull Prize in Pathology, St. Bartholomew’s and the Royal London Hospital School of Medicine and Dentistry 
 
2007 Best Service Award - Medical Officer (Nov 06 to Apr 07), Singapore General Hospital 
 
2008 Singhealth Talent Development Fund Award 
 
2008 National Medical Research Council Fellowship Award, Awarded by Ministry of Health, Singapore

Clinical Fellowship to the Drug Development Unit, Royal Marsden Hospital, UK 
 
2008 European Society of Medical Oncology (ESMO) Congress Travel Grant Award 
 
2008 Best Poster Award (33rd ESMO Congress) 
 
2008 American Society of Clinical Oncology (ASCO) Cancer Foundation Merit Award (Molecular Markers Meeting) 
 
2009 ESMO Translational Research Unit Visit Fellowship, Institut Jules Bordet, Brussels, Belgium 
 
2009 European School of Oncology Travel Grant Award (ECCLU) 
 
2009 AACR-ECCO-ASCO Fellowship, FLIMS 11 “Methods in Clinical Cancer Research” 
 
2009 AACR Scholarship, “Molecular Biology in Clinical Oncology: A Workshop” 
 
2009 ASCO Cancer Foundation Young Investigator Award 
 
2010 ASCO Cancer Foundation Merit Award (Annual Meeting) 
 
2011 Singapore Health Quality Service Award 
 
2013 Japan Cancer Association 72nd Annual Meeting Travel Grant Award

Publications and Research Trials
  • Tan DS, Wang W, Leong HS, Sew PH, Lau DP, Chong FT, Krisna SS, Lim TKH, Iyer NG. Tongue carcinoma infrequently harbor common actionable genetic alterations.  BMC Cancer. 2014 Sep 19;14:679. doi: 10.1186/1471-2407-14-679.

  • Krishnan VG, Ebert PJ, Ting JC, Lim E, Wong SS, Teo AS, Yue YG, Chua HH, Ma X, Loh GS, Lin Y, Tan JH, Yu K, Zhang S, Reinhard C, Tan DS, Peters BA, Lincoln SE, Ballinger DG, Laramie JM, Nilsen GB, Barber TD, Tan P, Hillmer AM, Ng PC.  Whole-Genome Sequencing of Asian Lung Cancers: Second-Hand Smoke Unlikely to Be Responsible for Higher Incidence of Lung Cancer among Asian Never-Smokers. Cancer Res. 2014 Sep 4.

  • Leong HS, Chong FT, Sew PH, Lau DP, Wong BH, Teh BT, Tan DS, Iyer NG.  Targeting Cancer Stem Cell Plasticity Through Modulation of Epidermal Growth Factor and Insulin-Like Growth Factor Receptor Signaling in Head and Neck Squamous Cell Cancer.  Stem Cells Transl Med. 2014 Jul 14  #joint corresponding authors

  • Khoo BL#, Warkiani ME#, Tan DS#, Bhagat AA, Irwin D, Lau PX, Lim AST, Lim KH, Krisna SS, Lim WT, Yap YS, Lee SC, Soo RA, Han JY, Lim CT.  Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.  Plos One (2014)  #joint first authors

  • Shaw AT, Kim DW, Mehra R, Tan DSW, Felip E, Chow LQ, Camidge R, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau Y, Goldwasser M, Boral AL, Engelman JA . Ceritinib in Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer.  New England Journal of Medicine Mar 27;370(13):1189-97. 

  • Tan DS#, Camilleri-Broet S#, Tan EH, Alifano M, Lim WT, Bobbio A, Zhang SL, Ng QS, Ang MK, Iyer NG, Takano A, Lim KH, Fancois-Regnard JP, Tan P, Broet P.  Intertumour heterogeneity of non-small cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. International Journal of Cancer (in press) #joint first authors

  • Tan DS, Haaland B, Gan JM, Tham SC, Sinha I, Tan EH, Lim KH, Takano A, Krisna SS, Thu MM, Liew HP, Ullrich A, Lim WT, Chua BT.  Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer.  Mol Cancer. 2014 Jan 24;13(1):13.

  • Tan DS, Montoya J, Ng QS, Chan KS, Oon L, Krisna SS, Takano A, Lim WT, Tan EH, Lim KH.  Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary. J Clin Oncol. 2013 May 10;31(14):e237-9. 

  • Tan DS, Gerlinger M, Teh BT, Swanton CS. (2010)  Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA intereference. Eur J Cancer; 46(12):2166-77.

  • Tan DS, Thomas G, Garrett M, Banerji U, de Bono JS, Kaye SB, Workman P (2009) Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. Cancer J. Sep-Oct;15(5):406-20.

Fix an appointment with this doctor.
Book appointment online
64368088